Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Admilparant long-term extension in pulmonary fibrosis
2025-522373-10-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 33
01
Overview
Phase 3, open-label, single-arm trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse events and deaths and Laboratory, ECG, and vital sign changes. Planned start Jun 2026; status: authorised.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2025-522373-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522373-10-00.